Advice
Following a full submission
Mycophenolate sodium (Myfortic) is accepted for use within NHS Scotland for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants in combination with ciclosporin and corticosteroids.
It is restricted to use by transplant specialists as part of an Immunosuppressive regimen.
Download detailed advice44KB (PDF)
Medicine details
- Medicine name:
- Mycophenolate sodium (Myfortic®)
- SMC ID:
- 144/04
- Indication:
- In combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 January 2005